Rare Diseases ENVIRONMENT
PATIENT JOURNEY
ITALIAN ENVIRONMENT FOR RARE DISEASES
that as many as 5000 to 7000 distinct rare diseases exist, affecting for most of them a very small number of patients.
is defined as rare in Europe when it affects fewer than 1 in 2000 people.
for most of these diseases, for most of these patients and their families, are still to be invented, registered and marketed.
European Commission on Public Health defines rare diseases as
- life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them -
Rare Insight Consulting
- will help new start-up biopharmaceutical companies establish their presence in Italy & Europe, as well as assisting well-established companies to bring solutions to people suffering from severe or orphan diseases. -
Orphan/Biotech Drugs market
experience
of the commercial process in the
pharmaceutical environment
in pharma companies start-up
and management
Leonardo Calzetti
Founding Partner
Leonardo is founder of BluPhytal, a company which, through its Rare Insight Consulting division, supports healthcare companies to develop their presence in the Orphan Disease arena.
From 2016 to 2019 Leonardo has served as Head of Global Rare Diseases Franchise at Chiesi, managing the Strategic Marketing process and supporting Business Development activities.
From 2008 to 2015 Leonardo has created and developed the Italian affiliate of Swedish Orphan Biovitrum (SOBI), managing also Greece and Malta territories. In this role Leonardo has represented SOBI into Assobiotec (Italian Association for the Development of Biotechnologies) becoming member of the directive board.
Previously has spent 20 years in Chiesi Farmaceutici in positions with increasing responsibility in operational and strategic marketing, mainly in rare or severe diseases.
Rare Insight has been and is an extremely valuable partner for Laboratoires CTRS.
They have effectively supported us in all phases (early access, price & reimbursement, launch strategy and tactics in the Italian market, KOL mapping, effective presentation of Orphacol advantages to treating physicians) allowing Orphacol to reach 100% of eligible patients.
Marco Liguori – Head of International Commercial Operations
